These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 35158947)

  • 1. The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.
    Ghasemi DR; Fleischhack G; Milde T; Pajtler KW
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current medulloblastoma subgroup specific clinical trials.
    Thompson EM; Ashley D; Landi D
    Transl Pediatr; 2020 Apr; 9(2):157-162. PubMed ID: 32477916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.
    Menyhárt O; Giangaspero F; Győrffy B
    J Hematol Oncol; 2019 Mar; 12(1):29. PubMed ID: 30876441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
    Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
    Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
    Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
    Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
    Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
    Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches.
    Menyhárt O; Győrffy B
    Cancer Metastasis Rev; 2020 Mar; 39(1):211-233. PubMed ID: 31970590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
    Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
    J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
    Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
    PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
    Cambruzzi E
    Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathology, diagnostics, and classification of medulloblastoma.
    Orr BA
    Brain Pathol; 2020 May; 30(3):664-678. PubMed ID: 32239782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced MRI Findings in Medulloblastomas: Relationship to Genetic Subtypes, Histopathology, and Immunohistochemistry.
    Reis J; Stahl R; Zimmermann H; Ruf V; Thon N; Kunz M; Liebig T; Forbrig R
    J Neuroimaging; 2021 Mar; 31(2):306-316. PubMed ID: 33465267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights.
    Khatua S; Song A; Citla Sridhar D; Mack SC
    Curr Neuropharmacol; 2018; 16(7):1045-1058. PubMed ID: 29189165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential response of SHH-expressing adult medulloblastomas to the sonic hedgehog inhibitor vismodegib: whole-genome analysis.
    Lou E; Nelson AC; Kool M
    Cancer Biol Ther; 2019; 20(11):1398-1402. PubMed ID: 31423907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
    Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
    J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD271
    Liang L; Coudière-Morrison L; Tatari N; Stromecki M; Fresnoza A; Porter CJ; Del Bigio MR; Hawkins C; Chan JA; Ryken TC; Taylor MD; Ramaswamy V; Werbowetski-Ogilvie TE
    Cancer Res; 2018 Aug; 78(16):4745-4759. PubMed ID: 29930101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
    Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
    J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of medulloblastoma therapy to personalized medicine.
    Sengupta S; Pomeranz Krummel D; Pomeroy S
    F1000Res; 2017; 6():490. PubMed ID: 28713553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.